Development of R7BP inhibitors through cross-linking coupled mass spectrometry and integrated modeling

Area of Science:

• Structural biology
• Pharmacology
• Biochemistry

Background:

• Protein-protein interaction (PPI) networks are crucial therapeutic targets.
• Drug development for PPIs is hindered by insufficient structural data for many proteins and complexes.
• R7BP is a key regulator of itch sensation.

Purpose of the Study:

• To develop an effective approach for obtaining structural data on R7BP and its interaction interfaces.
• To integrate cross-linking mass spectrometry (XL-MS) with modeling techniques.
• To develop antibody inhibitors for the R7BP and RGS7/Gβ5 duplex interaction.

Main Methods:

• Integration of cross-linking mass spectrometry (XL-MS) with various modeling techniques.
• Development of antibody inhibitors targeting specific protein interfaces.
• Characterization of binding and inhibitory efficiency using surface plasmon resonance spectroscopy and dominant-negative constructs.

Main Results:

• Successful acquisition of structural data for R7BP and its interaction interfaces.
• Development of effective antibody inhibitors for the R7BP and RGS7/Gβ5 duplex.
• Demonstration of the approach's utility in studying protein interactions without complete structural information.

Conclusions:

• The integrated XL-MS and modeling approach provides valuable structural insights for PPIs.
• This method facilitates the development of therapeutic modulators, such as antibody inhibitors.
• The approach has broad applicability for drug discovery targeting PPIs, especially when structural data is limited.